Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The subjective physical effects of DXM can be broken down into nine components all of which progressively intensify proportional to dosage.
The head space of DXM is often described as particularly impairing, disorientating and generally less clear headed in comparison to that of MXE and Ketamine.
This substance does not enhance visual stimuli; instead it tends to degrade and decrease visual aptitude in a variety of ways.
DXM exhibits a full array of dissociative distortions and alterations in visual perception.
The visual geometry found within DXM can be described as intricate in complexity, fast in movement, soft in edges, rounded and angular in corners, large in size, immersive in presence and very brightly coloured in scheme when compared to that of MXE.
At high dosages, DXM can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used psychedelics.
The auditory effects of DXM are common in their occurrence and exhibit a range of effects.
Primarily hepatic via two parallel pathways. CYP2D6 catalyzes O-demethylation to dextrorphan, accounting for approximately 80% of this metabolic route. CYP3A4 mediates N-demethylation to 3-methoxymorphinan, responsible for roughly 90% of that pathway. Both primary metabolites subsequently converge to form 3-hydroxymorphinan through further demethylation. Dextrorphan and 3-hydroxymorphinan undergo O-glucuronidation and O-sulfation for elimination. Dextrorphan achieves plasma concentrations up to 100-fold higher than the parent compound in extensive metabolizers, functioning as the principal mediator of dissociative effects with approximately 2-3 fold greater NMDA receptor affinity than dextromethorphan itself.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Psychological addiction is uncommon but documented. Some users develop craving and emotional dependence with regular use, finding it difficult to stop. DXM is considered less addictive than opioid-based cough suppressants like codeine, though it is classified as habit-forming.
Physical dependence is not well-established. Long-term regular users report withdrawal symptoms similar to antidepressant discontinuation syndrome, including disturbances in sleep, senses, movement, mood, and cognition. Some users report a 1-2 week hangover period after stopping regular use. Life-threatening withdrawal has not been documented.
Pure DXM has a relatively wide safety margin. Risk of death is estimated to begin at approximately 2,200-2,500 mg, though only a handful of fatalities have been documented from DXM alone without other substances. Most fatal overdoses involve combination with other drugs or adulterants present in DXM-containing products. Exact lethal doses in confirmed fatalities remain uncertain. Long-term health risks of high-dose use are not well documented.
Chronic heavy use over extended periods may cause cognitive deficits including impaired episodic memory, learning difficulties, and abnormalities in visual processing and abstract language comprehension; the theory that DXM causes Olney's lesions (brain vacuolization) remains inconclusive in humans, and oral administration in rats did not produce such lesions.
Acute increases in systolic and diastolic blood pressure along with increased heart rate occur at high doses; serious cardiovascular events are primarily associated with overdose or products containing stimulant adulterants.
Urinary retention becomes increasingly likely at higher doses and may result in complete inability to urinate at very high doses; this is an acute effect during intoxication rather than chronic damage.
Psychotic symptoms including delusions, paranoia, and detachment from reality occur at high doses, particularly at third plateau and above. Plateau sigma (extended high-dose sessions) carries high risk of delirium and psychosis. Extended heavy use over days or weeks may cause lasting delusional, paranoid, and psychotic ideation persisting for weeks, months, or longer after cessation.
Seizures have been reported in overdose scenarios. Many reported seizure cases involve adulterants such as chlorpheniramine maleate rather than DXM itself. States of agitation with epileptic episodes may occur at very high doses.
The racemic parent compound racemethorphan was first described in patent applications by Hoffmann-La Roche in Switzerland and the United States in 1946 and 1947, respectively, with a patent granted in 1950. Resolution of the two isomers using tartaric acid was published in 1952. Dextromethorphan…
Available over-the-counter from pharmacies. Import restrictions may apply to DXM-only products. Robitussin Dry Cough Forte is among the available DXM-only preparations.
Available over-the-counter without prescription and without age restriction. DXM-only products available at some pharmacies.
Specifically listed as exempt from the Controlled Drugs and Substances Act. Available over-the-counter without prescription and can legally be obtained in powder form.
Some pharmacies require prescription for tablet formulations while liquid preparations may be available without prescription.
Products containing more than 10 mg per dose are controlled and require a prescription. Combination products with lower DXM content may be available over-the-counter.
Listed in the medicinal product list and restricted to pharmacy sales. Can be purchased without prescription and without age restriction. Some products require a permit to sell.
Not listed in the Betäubungsmittelgesetz (Federal Law on Narcotics). Sales restricted to pharmacies but available without prescription in syrup and tablet forms.
Cough syrups containing DXM available over-the-counter. Pure DXM capsules require a prescription.
Available in popular over-the-counter cough medicines without prescription.
Among the few countries where DXM-containing antitussive preparations face significant restrictions beyond standard pharmacy controls.
Not listed in the General Health Law (Ley General de Salud) as a controlled substance. Classified as a category VI drug under Article 226, meaning DXM-only products can be sold without prescription at any retailer, including non-pharmacy establishments.
Available over-the-counter without identification requirements. Products including Robitussin Dry Cough Forte widely available.
Pure DXM preparations require a prescription. Liquid formulations and products marketed as Tussin are available over-the-counter, though enforcement varies.
Classified as a Class A prescription medication. Cannot be purchased without a valid prescription from a physician.
Classified as a controlled narcotic substance. The cough medicine Tussidyl containing DXM was withdrawn from Swedish sales in 1999 due to abuse concerns and associated risks. No longer marketed in Sweden.
Available behind the pharmacy counter. A prescription is obtained from the dispensing pharmacist at point of sale.
Specifically exempted from control under the Misuse of Drugs Act 1971 and 2001. Restricted to pharmacy sales at the discretion of the pharmacist. Purchasers typically must be at least 16 years of age. Multiple purchases may be refused or questioned.
Not listed in the Suchtmittelgesetz (Federal Law on Narcotics). Sales restricted to pharmacies but preparations are available without prescription.
DXM-containing products sold over-the-counter without prescription.
Classified as a Class II psychotropic substance effective July 1, 2024. Single-ingredient DXM medications restricted to hospital sales. Combination products containing DXM with other active ingredients such as guaifenesin remain available over-the-counter.
The DXM-containing product Dexofan is classified as a prescription type A medication, requiring a doctor's prescription for purchase.
Among the few countries where DXM-containing antitussive preparations face significant restrictions beyond standard pharmacy controls.
Available at pharmacies without a prescription but kept behind the counter rather than on open shelves.
Does not require a prescription but purchasers must provide identification to the pharmacy. Some product lines have been discontinued from the market.
DXM-only and DXM combination products available over-the-counter without prescription.
DXM is legal and has been available in various retail settings. Historically sold in specialized shops.
Classified as a controlled medication available from pharmacies and clinics. Recreational use is explicitly prohibited under law.
As of January 1, 2011, no longer available over-the-counter outside of pharmacies. Pharmacies are required to record buyer identification information.
Available over-the-counter in tablet, capsule, and syrup forms. Purchasers must be over 18 years of age and are limited to purchasing no more than 360 mg of DXM per transaction at a single pharmacy.
Listed as a Schedule III controlled substance following government anti-DXM campaigns. Subject to tighter restrictions than in most other countries.
Listed as a controlled psychotropic substance. However, combination products meeting specific requirements are exempt from control if the single dose contains 7.5-15 mg and daily usage does not exceed 60 mg.
Classified as a category B pharmaceutical, generally requiring a prescription or pharmacist consultation. Reclassified in 2018 from category C, which had previously allowed over-the-counter purchase.
DXM-only products require a prescription for purchase. Availability may be limited.
Specifically excluded from the Controlled Substances Act of 1970. Sold over-the-counter and regulated by the FDA when sold for human consumption. Many states and retailers require purchasers to be 18 or older. California enacted legislation effective January 1, 2012 prohibiting sales to minors without prescription. Illinois passed legislation effective January 1, 2007 restricting sales to FDA-compliant over-the-counter formulations. New York prohibited sales to those under 18 as of September 2013. Selling pure powder has resulted in convictions for selling misbranded drugs.
11 sources cited
